PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 101-125 of 369

  • Tenalisib
    Cat. No.
    A16799

    Tenalisib (RP6530)

    Synonyms: RP-6530

    Tenalisib, also known as RP6530, is a potent and selective dual PI3Kδ/γ inhibitor that inhibited growth of B-cell lymphoma cell lines with a concomitant reduction in the downstream biomarker, pAKT.

    1 mg
    $25.00
    2 mg
    $40.00
    All 8 sizes
  • IPI-3063
    Cat. No.
    A16800

    IPI-3063

    IPI-3063 is a potent and selective p110δ inhibitor with biochemical IC50 of 2.5±1.2 nM and IC50 values for the other class I PI3K isoforms (p110α, p110β, p110γ) are at least 400-fold higher.

    1 mg
    $30.00
    2 mg
    $50.00
    All 8 sizes
  • 2-D08
    Cat. No.
    A16852

    2-D08

    2-D08 is a cell permeable, mechanistically unique inhibitor of protein sumoylation. It is also inhibits Axl, IRAK4, ROS1, MLK4, GSK3β, RET, KDR and PI3Kα with IC50 values of 0.49, 3.9, 5.3, 9.8, 11, 11, 17 and 35 nM respectively in biochemical assays.

    5 mg
    $45.00
    10 mg
    $80.00
    All 6 sizes
  • SAR260301
    Cat. No.
    A16877

    SAR260301

    SAR260301 is potent and selective Class I phosphatidylinositol-3-kinase (PI3K)β specific inhibitor with an IC50 of 52 nM for this isoform.

    2 mg
    $30.00
    5 mg
    $55.00
    All 8 sizes
  • Vps34-IN-2
    Cat. No.
    A16933

    Vps34-IN-2

    Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively.

    1 mg
    $185.00
    2 mg
    $355.00
    All 7 sizes
  • MTX-211
    Cat. No.
    A18324

    MTX-211

    MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the treatment of KRAS mutant colorectal cancer.

    1 mg
    $50.00
    2 mg
    $90.00
    All 9 sizes
  • P110δ-IN-1
    Cat. No.
    A18348

    P110δ-IN-1

    Synonyms: ME401; PWT143

    P110δ-IN-1 is a potent and selective inhibitor of P110δ extracted from patent WO 2014055647 A1, with an IC50 of 8.4 nM.

    1 mg
    $35.00
    5 mg
    $80.00
    All 6 sizes
  • PQR-530
    Cat. No.
    A19209

    PQR-530

    PQR-530 is a potent, oral and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, exhibiting antitumor activity.

    1 mg
    $20.00
    5 mg
    $60.00
    All 7 sizes
  • PI3Kdelta inhibitor 1
    Cat. No.
    A19249

    PI3Kdelta inhibitor 1

    PI3Kdelta inhibitor 1 (Compound 5d) is a potent, selective and orally available PI3Kδ inhibitor with an IC50 of 1.3 nM.

    1 mg
    $200.00
    5 mg
    $500.00
    All 6 sizes
  • PI3Kδ-IN-1
    Cat. No.
    A19582

    PI3Kδ-IN-1

    PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.

    1 mg
    $50.00
    5 mg
    $140.00
    All 6 sizes
  • PI3Kγ inhibitor 2
    Cat. No.
    A19606

    PI3Kγ inhibitor 2

    PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective PI3Kγ inhibitor with a Ki of 4 nM.

    1 mg
    $315.00
    5 mg
    $955.00
    All 6 sizes
  • PI3K/mTOR Inhibitor-2
    Cat. No.
    A19621

    PI3K/mTOR Inhibitor-2

    PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity.

    1 mg
    $45.00
    5 mg
    $140.00
    All 8 sizes
  • CHMFL-PI3KD-317
    Cat. No.
    A19990

    CHMFL-PI3KD-317

    CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM.

    1 mg
    $85.00
    5 mg
    $220.00
    All 7 sizes
  • PI3K/mTOR Inhibitor-1
    Cat. No.
    A20055

    PI3K/mTOR Inhibitor-1

    PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively. Antitumor activity.

    1 mg
    $315.00
    5 mg
    $955.00
    All 6 sizes
  • IITZ-01
    Cat. No.
    A20192

    IITZ-01

    Synonyms: Autophagy inhibitor IITZ-01

    IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.

    5 mg
    $30.00
    10 mg
    $50.00
    All 7 sizes
  • Linperlisib
    Cat. No.
    A20275

    Linperlisib (YY-20394)

    Synonyms: YY-20394

    Linperlisib is a potent and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM.

    1 mg
    $25.00
    2 mg
    $35.00
    All 8 sizes
  • NSC781406
    Cat. No.
    A20402

    NSC781406

    NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα.

    1 mg
    $20.00
    2 mg
    $30.00
    All 9 sizes
  • GDC-0326
    Cat. No.
    A20437

    GDC-0326

    GDC-0326 is a potent and selective PI3Kα inhibitor with a Ki of 0.2 nM.

    1 mg
    $25.00
    2 mg
    $40.00
    All 8 sizes
  • (Rac)-AZD 6482
    Cat. No.
    A20629

    (Rac)-AZD 6482

    Synonyms: (Rac)-KIN-193; KIN193; AZD6482

    Rac)-AZD 6482 ((Rac)-KIN-193) is a less active racemate of AZD 6482. AZD 6482 is a potent and selective p110β inhibitor with an IC50 of 0.69 nM.

    5 mg
    $290.00
    10 mg
    $535.00
    All 6 sizes
  • PI3K-IN-6
    Cat. No.
    A20687

    PI3K-IN-6

    PI3K-IN-6 (compound 20a) is an oral active and highly selective phosphoinositide 3-kinase (PI3K) β/δ inhibitor, with IC50 values of 7.8 nM/5.3 nM for PI3K β/δ, respectively.

    1 mg
    $200.00
    5 mg
    $500.00
    All 6 sizes
  • LAS191954
    Cat. No.
    A20691

    LAS191954

    LAS191954 is a potent, selective and orally active PI3Kδ inhibitor for inflammatory diseases treatment, with an IC50 of 2.6 nM.

    1 mg
    $315.00
    5 mg
    $955.00
    All 6 sizes
  • OSU-T315
    Cat. No.
    A20870

    OSU-T315

    OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).

    1 mg
    $90.00
    2 mg
    $140.00
    All 9 sizes

Items 101-125 of 369

Added to your cart

View Cart Checkout

    Loading...